Envestnet Asset Management Inc. Lowers Stock Position in Certara, Inc. (NASDAQ:CERT)

Envestnet Asset Management Inc. decreased its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 9.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 414,056 shares of the company's stock after selling 43,117 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.26% of Certara worth $4,410,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Certara by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company's stock valued at $132,455,000 after buying an additional 38,068 shares during the period. Teacher Retirement System of Texas grew its position in Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock valued at $48,542,000 after buying an additional 557,348 shares during the period. Massachusetts Financial Services Co. MA grew its position in Certara by 4.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company's stock valued at $43,494,000 after buying an additional 182,042 shares during the period. Brown Brothers Harriman & Co. grew its position in Certara by 63.8% during the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock valued at $40,668,000 after buying an additional 1,487,998 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Certara by 169.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock valued at $21,248,000 after buying an additional 1,253,385 shares during the period. Institutional investors own 73.96% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on CERT. Barclays reduced their price target on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. TD Cowen initiated coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Stephens reiterated an "overweight" rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. KeyCorp increased their target price on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Finally, William Blair reiterated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $15.17.

Certara Price Performance

Shares of Certara stock traded up $0.16 on Tuesday, reaching $13.89. The stock had a trading volume of 1,816,642 shares, compared to its average volume of 1,228,513. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.94. The company has a market cap of $2.24 billion, a P/E ratio of -69.45, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The business's 50 day moving average is $11.65 and its two-hundred day moving average is $11.61.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.